These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
180 related items for PubMed ID: 1410128
1. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, Patterson J, Hanson MT, Siegfried K, Goodwin GM. Psychopharmacology (Berl); 1992; 108(1-2):103-9. PubMed ID: 1410128 [Abstract] [Full Text] [Related]
7. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Almkvist O, Jelic V, Amberla K, Hellström-Lindahl E, Meurling L, Nordberg A. Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238 [Abstract] [Full Text] [Related]
10. Velnacrine maleate improves delayed matching performance by aged monkeys. Jackson WJ, Buccafusco JJ, Terry AV, Turk DJ, Rush DK. Psychopharmacology (Berl); 1995 Jun; 119(4):391-8. PubMed ID: 7480518 [Abstract] [Full Text] [Related]
11. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease. Pomara N, Deptula D, Singh R. Psychopharmacol Bull; 1991 Jun; 27(3):301-7. PubMed ID: 1775603 [Abstract] [Full Text] [Related]
12. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Håkansson L. Acta Neurol Scand Suppl; 1993 Jun; 149():7-9. PubMed ID: 7907455 [Abstract] [Full Text] [Related]
18. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD. Neuroreport; 2002 Jan 21; 13(1):83-7. PubMed ID: 11924899 [Abstract] [Full Text] [Related]
19. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease. Cutler NR, Sramek JJ, Murphy MF, Nash RJ. J Geriatr Psychiatry Neurol; 1992 Jan 21; 5(4):192-4. PubMed ID: 1418362 [Abstract] [Full Text] [Related]
20. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study". Cutler NR, Sramek JJ. Alzheimer Dis Assoc Disord; 1995 Jan 21; 9(3):139-45. PubMed ID: 8534412 [Abstract] [Full Text] [Related] Page: [Next] [New Search]